Liavium™-CA1

USES

LIAVIUM™-CA1 is indicated for the management of pain and clinical signs associated with Chiari-like malformation and syringomyelia in dogs. Conditionally approved by FDA pending a full demonstration of effectiveness under application number 141-606.

Federal law restricts this drug to use by or on the order of a licensed veterinarian. It is a violation of Federal law to use this product other than as directed in the labeling. See full prescribing information for complete dosing and administration instructions.

PRODUCT INFORMATION

Active Ingredient(s): Pregabalin

IMPORTANT SAFETY INFORMATION:
Liavium-CA1 (pregabalin chewable tablets) is conditionally approved by FDA pending a full demonstration of effectiveness under application number 141-606. Liavium™-CA1 is a Schedule V controlled substance and should be handled and stored according to federal and state controlled-substance requirements. Based on publications in the scientific literature, the following adverse reactions are associated with administration of pregabalin in dogs: somnolence, increased appetite, decreased activity, increased water intake, decreased body temperature or hypothermia, ataxia and sedation. LIAVIUM™-CA1 has not been evaluated in dogs with renal disease. Pregabalin is excreted by the kidneys and an adjustment of the pregabalin dose in dogs with renal disease may be necessary. LIAVIUM™-CA1 has not been evaluated in dogs that are pregnant, nursing or intended for breeding. If the dog vomits after product administration, avoid skin contact with vomit and any tablet remnants, use impervious gloves during cleaning up and wash hands afterwards. Women who are pregnant who may become pregnant or are breastfeeding should take particular care to avoid contact with pregabalin. Not for human use. Keep out of reach of children. See prescribing information for complete details regarding adverse events, warnings, and precautions.